Scientists target ‘zombie’ cells to reverse liver damage in mice

Targeting Senescent Cells in Liver Disease

Scientists are exploring the potential of senolytic therapies to reverse liver damage in mice by targeting senescent cells, known as ‘zombie’ cells, which are linked to aging-related organ dysfunction. A study published in Nature Aging highlights the role of senes, positioning them as a key factor in chronic diseases. This research contributes to ongoing efforts in regenerative medicine to address cellular senescence, a hallmark of aging, by demonstrating that eliminating these dysfunctional cells could mitigate age-related organ decline, with liver disease serving as a critical model for testing this approach.

Experimental Findings in Mice

The study employed ABT-26, a drug previously investigated for its ability to target senescent cells, in mice with fatty liver disease. Administering the drug led to measurable improvements in liver health, including a 30–40% reduction in liver size and weight, alongside a 25% decrease in body weight. Fat deposits and inflammatory markers were also reduced, indicating the drug’s capacity to reverse pathological changes. In aging mice, 15–20% of liver macrophages exhibited senescent markers, compared to under 5% in younger mice, correlating with increased inflammation and fat accumulation. These findings suggest that senescent macrophages may drive liver pathology in aging organisms.

Implications for Human Health

While the study focuses on mice, its implications for human health are significant. Chronic liver disease, including non-alcoholic fatty liver disease (NAFLD), affects over 25% of the global population. The research suggests that senescent macrophages could contribute to similar conditions in humans, potentially opening new therapeutic avenues. Senolytics like dasatinib and quercetin are already in early-phase human trials for age-related conditions such, as kidney disease and frailty, though no liver-specific trials have been mentioned. This underscores both the potential and challenges of translating preclinical results to human applications. The Mayo Clinic’s research on senescent cells in severe fatty liver disease further supports the clinical relevance of this work, as inflammation from these cells is linked to liver failure.

Mechanisms of Cellular Senescence

Cellular senescence involves complex pathways, including the p53/p21 and p16INK4a pathways, which lead to the secretion of pro-inflammatory factors, contributing to tissue dysfunction. This study aligns with broader research on senolytics for conditions like osteoarthritis, pulmonary fibrosis, and age-related cancers. A 2023 preclinical study found that senolytics could clear up to 70% of senescent cells in mice, reducing inflammation, but residual cells may rebound over time. This indicates that senolytics may require combination therapies for long-term efficacy. The study also connects senescent cells to age-related diseases through mechanisms such as mitochondrial dysfunction and RNA leakage, as observed in metabolic-associated steatotic hepatitis (MASH). These insights position senolytics as a potential component of anti-aging medicine.

Collaborative Research and Funding

The research was supported by the National Institutes of Health (NIH), reflecting the scientific community’s recognition of its potential. Collaborative efforts between institutions like UCLA and the Mayo Clinic highlight the interdisciplinary nature of this work. NIH funding underscores a broader commitment to advancing therapies for age-related diseases, with senolytics emerging as a promising area of investigation. These partnerships are critical for scaling research and translating findings from preclinical models to human applications. The involvement of federal agencies like the NIH signals regulatory and institutional support for further exploration of senolytic therapies.